CS
SION

Candriam SCA’s Sionna Therapeutics SION Stock Holding History

Candriam SCA’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
233,208
-3,605
-2% -$144K 0.05% 291
2026
Q1 		$9.49M Buy
+236,813
New +$9.04M 0.05% 286

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Candriam SCA's SION Position: Q2 2026 in Review

Candriam SCA reduced its Sionna Therapeutics (SION) stake by 1.5% in Q2 2026, selling an estimated $144K and leaving 233,208 shares worth $10.2M. The position accounts for 0.05% of the portfolio, ranked #291.

Candriam SCA first reported a position in SION in Q1 2026 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Candriam SCA held 233,208 shares of Sionna Therapeutics worth $10.2M as of Q2 2026.
  • Candriam SCA sold 3,605 Sionna Therapeutics shares in Q2 2026, an estimated $144K.
  • Sionna Therapeutics made up 0.05% of Candriam SCA's portfolio in Q2 2026, its #291 holding.
  • Candriam SCA first reported a position in Sionna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.